Valbiotis : A call on the market ahead of a 2024 market launch
>A capital increase of € 15m factoring in a discount of 20.1% - Valbiotis announced yesterday evening after the close of trade the launch of a capital increase with cancellation of the Preferential Subscription Right (PSR) for an amount of € 15m (3.4 million new shares) corresponding to 22% of the company's capitalisation. The subscription terms are known, i.e. one new share at a price of € 4.46, corresponding to a 20.1% discount to the closing price. The subscription...Valbiotis SA Formerly known as Valbiotis SAS. Valbiotis SA is a France-based company engaged in the biotechnology industry. The Company specializes in developing nutrition solutions designed to prevent cardiometabolic diseases and provide nutritional support for patients. It seeks to develop solutions designed to prevent type 2 diabetes, NASH, (non-alcoholic steatohepatitis) and obesity and to offer nutritional support. The Company prevents disease by developing products that reduce the risk factors of irreversible chronic diseases. It provides patient support through new-generation medical nutrition solutions containing patented substances with clinically proven effects. Its products are plant-based and undergo strict scientific and clinical tests in collaboration with academic research centers.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.